Galmed Pharmaceuticals Ltd
NASDAQ:GLMD

Watchlist Manager
Galmed Pharmaceuticals Ltd Logo
Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
Watchlist
Price: 0.833 USD -1.99% Market Closed
Market Cap: 4.6m USD

Galmed Pharmaceuticals Ltd
Investor Relations

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q4 2021
Call Date
May 2, 2022
Q4 2021 Earnings Call
No Analysis Available

This earnings call has not been analyzed yet.

If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.

Request Earnings Call Analysis
Earnings Call Recording
Other Earnings Calls

Management

Mr. Allen Baharaff
Co-Founder, President, CEO & Chairman
No Bio Available
Mr. Doron Cohen
Chief Financial Officer
No Bio Available
Mr. Guy Nehemya
COO & Data Protection Officer
No Bio Available
Mr. Yohai Stenzler CPA
Chief Accounting Officer
No Bio Available
Dr. Liat Hayardeny MBA, Ph.D.
Chief Scientific Officer
No Bio Available
Dr. Tali Gorfine
Medical Consultant
No Bio Available

Contacts

Address
TEL AVIV-YAFO
16 Ze'ev Tyomkin St. (4Th Fl.)
Contacts
+97236938448.0
www.galmedpharma.com